Which cancer therapies work best for the patients that urgently need them? By isolating single immune cells and analyzing their full functional response for the first time, the IsoPlexis platform can assess the effectiveness of therapeutics to find the best possible treatment. Developed by scientific leaders at Yale and Caltech, and further applied to clinical analysis by leaders at UCLA and Memorial Sloan Kettering Cancer Center, the IsoPlexis single-cell detection platform is improving the targeting of breakthrough treatments in cancer immunology and beyond.
the support and resources
- $17M total investment
- $3.025M from CI ($2,875,000 in equity and $400,000 facilities debt)
- Multiple rounds of funding, in concert with Spring Mountain Capital, North Sound and other institutional investors, totaling nearly $13M in capital raised, as well as $700,000 from four NIH-funded small business research grants
- CI’s Dan Wagner and Matt Storeygard joined the IsoPlexis board
- Help to find lab facilities and key team members
- Internship funding
- Press release coordination
IsoPlexis currently has 25 full-time employees. Leading academic labs and pharmaceutical companies are now using the IsoPlexis technology to improve the targeting of breakthrough treatments. Through partnerships with organizations including Yale, Caltech, UCLA, Kite Pharma and beyond, the IsoPlexis technology is helping to advance groundbreaking research and therapeutic development in immuno-oncology, other therapies in oncology, and other emerging disease areas.
“Connecticut Innovations has been a key partner of ours since the early days of founding IsoPlexis. As we have grown to our team of 25 people, raised funding and established commercial partners, multiple areas of the CI organization have helped connect me with key hires, lab facilities and equipment resources, and other sources of equity and non-dilutive funding.”
CEO AND CO-FOUNDER, ISOPLEXIS